A detailed history of Pinnacle Associates LTD transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Pinnacle Associates LTD holds 3,993 shares of CRSP stock, worth $184,835. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,993
Holding current value
$184,835
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$44.62 - $62.75 $178,167 - $250,560
3,993 New
3,993 $187,000
Q1 2024

Apr 26, 2024

BUY
$60.67 - $89.12 $79,477 - $116,747
1,310 Added 32.81%
5,303 $361,000
Q4 2023

Jan 19, 2024

BUY
$38.62 - $72.18 $154,209 - $288,214
3,993 New
3,993 $249,000
Q2 2023

Jul 26, 2023

BUY
$43.47 - $67.77 $187,616 - $292,495
4,316 New
4,316 $242,000
Q3 2022

Oct 31, 2022

BUY
$61.1 - $83.78 $269,817 - $369,972
4,416 New
4,416 $289,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.61B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Pinnacle Associates LTD Portfolio

Follow Pinnacle Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.